Erosive arthritis

Arthritis Research and Therapy

Volumn 9, Issue SUPPL.1, 2007, Pages

  Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ANTIINFLAMMATORY AGENT; DEATH RECEPTOR 4; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 7; OSTEOPROTEGERIN; PROSTAGLANDIN E2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTHRITIS; BINDING AFFINITY; BONE DEFECT; BONE EROSION; BONE MASS; BONE MINERALIZATION; BONE STRUCTURE; CARTILAGE DEGENERATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FUNCTIONAL STATUS; HAND RADIOGRAPHY; HISTOCHEMISTRY; HUMAN; IMMUNE RESPONSE; JOINT DESTRUCTION; LONG TERM CARE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; PROTEIN FUNCTION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; BONE; METABOLISM; PATHOLOGY; SYNOVIUM;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE AND BONES; HUMANS; RANK LIGAND; SYNOVIAL MEMBRANE;

EID: 34548448017     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2166     Document Type: Review

References (42)

1. Schett G Kiechl S Weger S Pederiva A Mayr A Petrangeli M Oberhollenzer F Lorenzini R Redlich K Axmann R High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study Arch Intern Med 2006, 166:2495-2501. 10.1001/archinte.166.22.2495 17159016
2. Gough AK Lilley J Eyre S Holder RL Emery P Generalized bone loss in patients with early rheumatoid arthritis Lancet 1994, 344:23-27. 10.1016/ S0140-6736(94)91049-9 7912297
3. Spector TD Hall GM McCloskey EV Kanis JA Risk of vertebral fracture in women with rheumatoid arthritis BMJ 1993, 306:558. 1677176 8461772
4. Hooyman JR Melton LJ III Nelson AM O'Fallon WM Riggs BL Fractures after rheumatoid arthritis. A population-based study Arthritis Rheum 1984, 27:1353-1361. 10.1002/art.1780271205 6508860
5. Bultink IE Lems WF Kostense PJ Dijkmans BA Voskuyl AE Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus Arthritis Rheum 2005, 52:2044-2050. 10.1002/art.21110 15986345
6. Bernstein CN Blanchard JF Leslie W Wajda A Yu BN The incidence of fracture among patients with inflammatory bowel disease. A population based cohort study Ann Intern Med 2000, 133:795-799. 11085842
7. Lougheed T The Vector Theory. Did rheumatoid arthritis originate in the New World? Arthritis News Magazine 1989, 7-2.
8. Weichselbaum A The finer changes of cartilage with fungus synovitis and caries of the joint ends [in German] Archiv Pathol Anat Physiol Klin Med 1878, 73:461-475. 10.1007/BF01995720
9. Arnett FC Edworthy SM Bloch DA McShane DJ Fries JF Cooper NS Healey LA Kaplan SR Liang MH Luthra HS The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302 3358796
10. Sharp JT Young DY Bluhm GB Brook A Brower AC Corbett M Decker JL Genant HK Gofton JP Goodman N How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985, 28:1326-1335. 10.1002/ art.1780281203 4084327
11. Scott DL Pugner K Kaarela K Doyle DV Woolf A Holmes J Hieke K The links between joint damage and disability in rheumatoid arthritis Rheumatology (Oxford) 2000, 39:122-132. 10.1093/rheumatology/39.2.122 10725061
12. Pincus T Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-trem clinical trials J Clin Epidemiol 1988, 41:1037-1041. 10.1016/0895-4356(88)90072-8 3060568
13. Welsing PM van Gestel AM Swinkels HL Kiemeney LA van Riel PL The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis Arthritis Rheum 2001, 44:2009-2017. 10.1002/ 1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L 11592361
14. Van der Heijde DM Joint erosions and patients with early rheumatoid arthritis Br J Rheumatol 1995, 34:74-78. 8535653
15. Hayer S Redlich K Korb A Hermmann S Smolen JS Schett G Tendosynovitis and osteoclast formation as the initial changes of preclinical inflammatory arthritis Arthritis Rheum 2007, 56:79-88. 10.1002/art.22313 17195210
16. Bromley M Woolley DE Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint Arthritis Rheum 1984, 27:968-975. 10.1002/art.1780270902 6236824
17. Gravallese EM Harada Y Wang JT Gorn AH Thornhill TS Goldring SR Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis Am J Pathol 1998, 152:943-951. 1858257 9546355
18. Pap T Aupperle KR Gay S Firestein GS Gay RE Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion Arthritis Rheum 2001, 44:676-681. 10.1002/ 1529-0131(200103)44:3<676::AID-ANR117>3.0.CO;2-6 11263783
19. Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T Elliott R Colombero A Elliott G Scully S Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998, 93:165-176. 10.1016/S0092-8674(00)81569-X 9568710
20. Kong YY Yoshida H Sarosi I Tan HL Timms E Capparelli C Morony S Oliveira-dos-Santos AJ Van G Itie A OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 1999, 397:315-323. 10.1038/16852 9950424
21. Dougall WC Glaccum M Charrier K Rohrbach K Brasel K De Smedt T Daro E Smith J Tometsko ME Maliszewski CR RANK is essential for osteoclast and lymph node development Genes Dev 1999, 13:2412-2424. 317030 10500098 10.1101/gad.13.18.2412
22. Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Luthy R Nguyen HQ Wooden S Bennett L Boone T Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3 9108485
23. Stolina M Guo J Faggioni R Brown H Senaldi G Regulatory effects of osteoprotegerin on cellular and humoral immune responses Clin Immunol 2003, 109:347-354. 10.1016/j.clim.2003.09.001 14697750
24. Shigeyama Y Pap T Kunzler P Simmen BR Gay RE Gay S Expression of osteoclast differentiation factor in rheumatoid arthritis Arthritis Rheum 2000, 43:2523-2530. 10.1002/ 1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z 11083276
25. Gravallese EM Manning C Tsay A Naito A Pan C Amento E Goldring SR Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor Arthritis Rheum 2000, 43:250-258. 10.1002/ 1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P 10693863
26. Ritchlin CT Haas-Smith SA Li P Hicks DG Schwarz EM Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J Clin Invest 2003, 111:821-831. 153764 12639988 10.1172/JCI200316069
27. Stolina M Adamu S Ominsky M Dwyer D Asuncion F Geng Z Middleton S Brown H Pretorius J Schett G RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis J Bone Miner Res 2005, 20:1756-1765. 10.1359/JBMR.050601 16160733
28. Lam J Takeshita S Barker JE Kanagawa O Ross FP Teitelbaum SL TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand J Clin Invest 2000, 106:1481-1488. 387259 11120755
29. Schett G Stolina M Bolon B Middleton S Adlam M Brown H Zhu L Feige U Zack DJ Analysis of the kinetics of osteoclastogenesis in arthritic rats Arthritis Rheum 2005, 52:3192-3201. 10.1002/art.21343 16200623
30. Redlich K Hayer S Ricci R David JP Tohidast-Akrad M Kollias G Steiner G Smolen JS Wagner EF Schett G Osteoclasts are essential for TNF-alpha-mediated joint destruction J Clin Invest 2002, 110:1419-1427. 151809 12438440 10.1172/JCI200215582
31. Pettit AR Ji H von Stechow D Muller R Goldring SR Choi Y Benoist C Gravallese EM TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis Am J Pathol 2001, 159:1689-1699. 1867076 11696430
32. Li P Schwarz EM O'Keefe Ma L Boyce BF Xing L RANK signaling is not required for TNF-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis J Bone Miner Res 2004, 19:207-213. 10.1359/ JBMR.0301233 14969390
33. Kong YY Feige U Sarosi I Bolon B Tafuri A Morony S Capparelli C Li J Elliott R McCabe S Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 1999, 402:304-309. 10.1038/46303 10580503
34. Redlich K Hayer S Maier A Dunstan CR Tohidast-Akrad M Lang S Turk B Pietschmann P Woloszczuk W Haralambous S Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin Arthritis Rheum 2002, 46:785-792. 10.1002/art.10097 11920416
35. Romas E Gillespie MT Martin TJ Involvement of receptor activator of NFκB ligand and tumor necrosis factor-a in bone destruction in rheumatoid arthritis Bone 2002, 30:340-346. 10.1016/ S8756-3282(01)00682-2 11856640
36. Lubberts E van den Bersselaar L Oppers-Walgreen B Schwarzenberger P Coenen-de Roo CJ Kolls JK Joosten LA van den Berg WB IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance J Immunol 2003, 170:2655-2662. 12594294
37. Herrak P Gortz B Hayer S Redlich K Reiter E Gasser J Bergmeister H Kollias G Smolen JS Schett G Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis Arthritis Rheum 2004, 50:2327-2337. 10.1002/art.20384 15248234
38. Komuro H Olee T Kuhn K Quach J Brinson DC Shikhman A Valbracht J Creighton-Achermann L Lotz M The osteoprotegerin/receptor activity of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage Arthritis Rheum 2001, 44:2768-2776. 10.1002/ 1529-0131(200112)44:12<2768::AID-ART464>3.0.CO;2-I 11762937
39. Bekker PJ Holloway D Nakanishi A Arrighi M Leese PT Dunstan CR The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 2001, 16:348-360. 10.1359/jbmr.2001.16.2.348 11204435
40. Bekker PJ Holloway DL Rasmussen AS Murphy R Martin SW Leese PT Holmes GB Dunstan CR DePaoli AM A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 2004, 19:1059-1066. 10.1359/JBMR.040305 15176987
41. McClung MR Lewiecki EM Cohen SB Bolognese MA Woodson GC Moffett AH Peacock M Miller PD Lederman SN Chesnut CH AMG 162 Bone Loss Study Group Denosumab in postmenopausal women with low bone mineral density N Engl J Med 2006, 354:821-831. 10.1056/NEJMoa044459 16495394
42. Cohen SB Valen P Ritchlin C Schechtman J Peterfy C van der Heijde D Zhou L Newmark R Tsuji W RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: Month 6 MRI results [abstract 2120] Arthritis Rheum 2006, 54(Suppl 9):S831.